Please login to the form below

Not currently logged in
Email:
Password:

head and neck cancer

This page shows the latest head and neck cancer news and features for those working in and with pharma, biotech and healthcare.

Merck signs separate agreements with Seattle Genetics for two cancer drugs

Merck signs separate agreements with Seattle Genetics for two cancer drugs

The ADC is currently in phase 2 clinical trials for breast cancer and other solid tumours, and will go on to be developed as a monotherapy and in combination with Merck ... head and neck, oesophageal and gastric cancer.

Latest news

  • Immutep slumps on latest efti data in breast cancer Immutep slumps on latest efti data in breast cancer

    lung cancer (NSCLC) and head and neck squamous cell carcinoma of the (HNSCC). ... Immutep certainly isn’t abandoning hope for efti in breast cancer, saying that it is holding on for overall survival data from the study – due in late 2020 – and is

  • AZ’s Imfinzi plus tremelimumab combo misses again AZ’s Imfinzi plus tremelimumab combo misses again

    cell lung cancer, bladder cancer and other tumour types. ... AZ notes the CTLA4 inhibitor remains in clinical trials in combination with Imfinzi in NSCLC, SCLC, bladder cancer, head and neck cancer and liver cancer.

  • Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer

    According to Pfizer, head and neck cancer is the sixth most common cancer in the world, with approximately 60% of people diagnosed at the locally advanced stage. ... Although Merck KGaA/Pfizer have suffered a setback in head and neck cancer, the partners

  • J&J’s bispecific lung cancer antibody nabs FDA breakthrough status J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

    other cancer types including a rare head and neck cancer known as sinonasal squamous cell carcinoma (SNSCC). ... and Boehringer Ingelheim’s Giotrif (afatinib), and also seem to resist cancer immunotherapies such as checkpoint inhibitors.

  • Immutep spikes on trial of its LAG-3 drug with Keytruda Immutep spikes on trial of its LAG-3 drug with Keytruda

    tumours. Most of those gains dissipated after the results of the mid-stage trial in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma of the (HNSCC) ... Immutep also has a phase 2b trial of efti ongoing – called AIPAC –

More from news
Approximately 7 fully matching, plus 108 partially matching documents found.

Latest Intelligence

  • Case study: What we're made of Case study: What we're made of

    This could be a side effect of a condition such as stroke, motor neurone disease, multiple sclerosis, learning disability, dementia, Parkinson’s disease, head and neck injury or cancer. ... We are effectively made of water and the consequences of

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    hope was that - without the brake of PD-1 – the edited cells would attack and defeat the cancer. ... The work was reported in the journal Nature and, since then, another Chinese group has tested a similar approach in head and neck cancer.

  • Immunisation politicised Immunisation politicised

    Practitioners were concerned that a hasty introduction of the vaccine would lead to lower participation rates in cervical cancer screening programmes using the pap smear test. ... For example, the remarkable silence around the fact that some strains of

  • Pharma deals in August 2015 Pharma deals in August 2015

    virus. INO-3112 generates killer T-cell responses to HPV 16 and 18 driven tumours and is in phase I / II clinical studies for cervical and head and neck cancers. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for

  • Lonafarnib: promising results in first-ever trial for progeria Lonafarnib: promising results in first-ever trial for progeria

    Lonafarnib and tipifarnib are the most successful of the FTIs, currently in Phase II development for breast cancer, and acute myeloid leukaemia and glioma, respectively. ... Development in other oncological indications (chronic myeloid leukaemia,

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... and neck cancer.

  • VentiRx appoints James Kyle Bryan as chief medical officer VentiRx appoints James Kyle Bryan as chief medical officer

    During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology. ... This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • What are you doing, Dave?

    parents. Google's DeepMind is exploring the use of AI in managing head and neck cancer, acute kidney injury, and detection of eye disease. ... The IBM Watson supercomputer is also being used to help manage cancer, as well as analysing data on genes,

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... Rubbing salt into BMS’s wounds, Merck's  Keytruda snagged

  • ASCO 2015: What you missed in Chicago

    Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics